Idorsia Ltd
IDIA
Rank in Stocks
#7690
Idorsia Ltd, a biopharmaceutical company, engages in the discovery,... Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The companyโs product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Share Price
$4.74
Last synced: 2026-11-12
Market Cap
$1.26B
Change (1 day)
-2.37%
Change (1 year)
19.13%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Idorsia Ltd (IDIA)
Category
Healthcare
Operating Margin for Idorsia Ltd (IDIA)
Operating Margin as of November 2026 TTM: -106.46%
According to Idorsia Ltd's latest financial reports, its current operating margin (TTM) is -106.46%. At the end of 2025 the company had an operating margin of -59.28%.
Operating Margin history for Idorsia Ltd from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -106.46% | 79.59% |
| 2025 | -59.28% | -71.25% |
| 2024 | -206.22% | 23.17% |
| 2023 | -167.43% | -79.75% |
| 2022 | -826.93% | -52.31% |
| 2021 | -1,734.15% | 203.08% |
| 2020 | -572.18% | -71.75% |
| 2019 | -2,025.36% | 230.86% |
| 2018 | -612.15% | 12,167.54% |
| 2017 | -4.99% | 0.00% |
| 2016 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -98.16% |
US
|
|
| 33.87% | -100.32% |
US
|
|
| -116.04% | -98.91% |
US
|
|
| 25.57% | -100.24% |
AU
|
|
| 31.23% | -100.29% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Idorsia Ltd's operating margin
What is Idorsia Ltd's operating margin?
Idorsia Ltd's operating margin is -106.46%, as of Nov 2026.
What was Idorsia Ltd's operating margin in 2025?
In 2025, Idorsia Ltd's operating margin was -59.28%, compared with -206.22% in 2024.
How has Idorsia Ltd's operating margin changed since 2020?
From 2020 to 2025, Idorsia Ltd's operating margin was highest in 2025 (-59.28%) and lowest in 2021 (-1,734.15%).
How does Idorsia Ltd's operating margin compare with similar companies?
Idorsia Ltd's operating margin (-106.46%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.